The phrase "adherence rate for" is correct and usable in written English.
It can be used when discussing the percentage of individuals or groups that follow a prescribed treatment, guideline, or protocol.
Example: "The adherence rate for the medication was significantly higher in the intervention group compared to the control group."
Alternatives: "compliance rate for" or "follow-through rate for".
The adherence rate for the hip protector trials was as follows: 44% at 11 months in the study by Ekman [41], 70% at 12 months in the study by Harada [42], 68% at 12 months in the study by Jantti [43], 79.7% throughout the study period (up to 26 months) in the study by Koike et al. 2009 [45], and 34% ("worst case estimate") in the study by Meyer [44].
Across all studied conditions, the adherence rate for duloxetine averaged 34.6% (mean MPR =0.54).
The mean adherence rate for the 35 participants who completed the intervention was 87%% (range 48 100%%).
For instance, Wöckel et al (2010) reported a 51.9% guideline adherence rate for the complete treatment received by patients with primary breast cancer.
A review of anti-hypertensive medicines found that the adherence rate for a single daily dose was significantly higher than adherence to multiple daily doses.
Figure 2 depicts the median adherence rate for all participants at each interview period as well as the lower and upper quartiles.
In a study conducted by the Center for Connected Health, in Boston, researchers showed that GlowCaps boosted adherence rates for patients taking blood pressure medicine from 65percentto98percentcent.
According to estimates from the U.S. Food and Drug Administration and the Centers for Disease Control, adherence rates for injected biologics range from around 40 to 70percentt.
Given the fact that the intensity of physical activity is prescribed (i.e., imposed) in most studies that have reported lower adherence rates for overweight and obese participants, it is reasonable to speculate that the lower adherence might be attributed, at least in part, to the decline in pleasure found under such conditions in the present study.
It is associated with a reduction in the number of days that patients use alcohol or opioids, in cravings and drug-seeking behaviors, and in healthcare utilization costs, as well as improved medication adherence rates for patients in substance use disorder (SUD) treatment programs and improved quality of life.
Adherence rates for RA medications are suboptimal.
